141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
Titel:
141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
Auteur:
Reinmuth, N. Goldman, J.W. Garassino, M.C. Chen, Y. Hotta, K. Poltoratskiy, A. Trukhin, D. Hochmair, M.J. Ji, J.H. Özgüroğlu, M. Statsenko, G. Voitko, O. Conev, N.V. Bondarenko, I. Mann, H. Xie, M. Shrestha, Y. Chugh, P. Dalvi, T. Paz-Ares, L.